Biotinylated Human Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein, His,Avitag?&Tag Free (MALS verified)
分子別名（Synonym）
Integrin alpha V beta 6,ITGAV&ITGB6
表達區(qū)間及表達系統(tǒng)（Source）
Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free (IT6-H82E4) is expressed from human 293 cells (HEK293). It contains AA Phe 31 - Val 992 (ITGAV) & Gly 22 - Asn 707 (ITGB6) (Accession # NP_002201.1 (ITGAV) & AAI21179.1 (ITGB6)).
Predicted N-terminus: Phe 31 (ITGAV) & Gly 22 (ITGB6)
蛋白結構（Molecular Characterization）
Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free, produced by co-expression of ITGAV and ITGB6, has a calculated MW of 114.7 kDa (ITGAV) and 79.6 kDa (ITGB6). Subunit ITGAV is fused with an acidic tail at the C-terminus and followed by a polyhistidine tag and an Avi tag (Avitag?) and subunit ITGB6 contains no tag but a basic tail at the C-terminus. The predicted N-terminus is Phe 31 (ITGAV) & Gly 22 (ITGB6). The non-reducing (NR) protein migrates as 135-150 kDa (ITGAV) and 82-95 kDa (ITGB6) respectively due to glycosylation.
標記（Labeling）
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標記度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
純度（Purity）
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介紹
整合素αVβ6是由β6亞基與αV亞基構成的異二聚體，可作為纖連蛋白（fibronectin）和肌腱蛋白（cytotactin）的受體，特異性識別配體中的R-G-D氨基酸序列。該整合素通過網格蛋白介導的內吞作用促進癌細胞侵襲，同時也是柯薩奇病毒A9型（coxsackievirus A9）、柯薩奇病毒B1型（coxsackievirus B1）及單純皰疹病毒-1型（HHV-1）的入侵受體。此外，它能結合TGF-β潛伏相關肽（LAP），從大分子潛伏復合體中激活TGF-β1或TGF-β3，此激活過程需與LTBP-1及纖連蛋白相互作用，并被PAR-1增強。
關鍵字： Integrin αVβ6;整合素αVβ6;Integrin αVβ6蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產業(yè)領域提供關鍵生物試劑產品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。